PDCD1 and non-small cell lung carcinoma: We demonstrate a significant correlation between the presence of irAEs and positive prognosis for patients with NSCLC after treatment with anti-PD-1 antibodies, suggesting that irAEs may be a clinical predictive biomarker for efficacy of anti-PD-1 therapy in NSCLC patients.